https://doi.org/10.4081/reumatismo.2023.1540
Adherence to treatment and associated factors in rheumatoid arthritis patients: a cross-sectional study from Iran
Accepted: 27 March 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The aim of this study is to evaluate adherence to treatment and its related risk factors among a sample of rheumatoid arthritis patients (RA) attending the rheumatology outpatient clinic of Kermanshah university of medical sciences. In this cross-sectional study, RA patients were asked to complete the Morisky questionnaire and 19-item compliance questionnaire for rheumatology (CQR). Patients were divided into two groups: adherent and non-adherent to treatment, based on the CQR questionnaire results. Demographic and clinical characteristics (age, sex, marital status, education level, economical condition, occupational status, place of residence, underlying diseases, type, and number of drugs) were compared between the two groups to investigate possible risk associations for poor adherence. 257 patients completed the questionnaires (mean age: 43.22, 80.2% female). 78.6% were married, 54.9% were housekeepers, 37.7% had tertiary education, 61.9% had moderate economic status, and 73.2% were residents of an urban area with a large population. Prednisolone was the most commonly used drug followed by non-steroidal anti-inflammatory drugs, sulfasalazine, hydroxychloroquine, and methotrexate. The mean score of the Morisky questionnaire was 5.528 (standard deviation=1.79). 105 patients (40.9%) were adherent to treatment based on the CQR questionnaire. High education level (college or university) was correlated with non-adherence to treatment [27 (25.71%) vs 70 (46.05%), p=0.004]. We concluded that the prevalence of non-adherence to treatment is 59.1% in rheumatoid arthritis patients in Kermanshah, Iran. Having a higher education level is a risk factor for poor treatment adherence. Other variables could not predict treatment adherence.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- E. Molteni, C. Pirone, F. Ceccarelli, C. Castellani, C. Alessandri, M. Di Franco, V. Riccieri, F.R. Spinelli, R. Priori, R. Scrivo, F. Conti, Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort , Reumatismo: Vol. 76 No. 2 (2024)
- A. Marchesoni, F. Cantini, Classification and clinical assessment , Reumatismo: Vol. 64 No. 2 (2012)
- A. Bortoluzzi, M. Padovan, I. Farina, E. Galuppi, F. De Leonardis, M. Govoni, Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre , Reumatismo: Vol. 64 No. 6 (2012)
- C. Montecucco, Outcome predictors in rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco, Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab , Reumatismo: Vol. 58 No. 2 (2006)
- C. Botsios, P. Ostuni, S. Todesco, Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience , Reumatismo: Vol. 57 No. 1 (2005)
- F. Lioté, Treatment of hyperuricemia, gout and other crystalline arthritidies , Reumatismo: Vol. 63 No. 4 (2011): Special issue • Microcrystalline Arthritis
- L. Riente, The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- A. Aghabiklooei, N. Zamani, H. Hassanian-Moghaddam, S. Nasouhi, M. Mashayekhian, Acute colchicine overdose: report of three cases , Reumatismo: Vol. 65 No. 6 (2013)
- A. Fassio, D. Gatti, P. Gisondi, G. Girolomoni, O. Viapiana, A. Giollo, M. Zamboni, M. Rossini, L. Idolazzi, Effects of secukinumab on serum adipocytokines: preliminary data , Reumatismo: Vol. 69 No. 3 (2017)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
You may also start an advanced similarity search for this article.
